0001562180-24-001226.txt : 20240209
0001562180-24-001226.hdr.sgml : 20240209
20240209174231
ACCESSION NUMBER: 0001562180-24-001226
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240207
FILED AS OF DATE: 20240209
DATE AS OF CHANGE: 20240209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Derakhshan Behrad
CENTRAL INDEX KEY: 0001853109
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40236
FILM NUMBER: 24616405
MAIL ADDRESS:
STREET 1: 3415 COLORADO AVE.
CITY: BOULDER
STATE: CO
ZIP: 80303
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc.
CENTRAL INDEX KEY: 0001710072
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 821725586
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1715 38TH ST
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 720-262-7002
MAIL ADDRESS:
STREET 1: 1715 38TH ST
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-02-07
false
0001710072
Edgewise Therapeutics, Inc.
EWTX
0001853109
Derakhshan Behrad
C/O EDGEWISE THERAPEUTICS, INC.
1715 38TH STREET
BOULDER
CO
80301
false
true
false
false
Chief Business Officer
true
Common Stock
2024-02-07
4
M
false
600.00
1.93
A
7620.00
D
Common Stock
2024-02-07
4
S
false
600.00
20.00
D
7020.00
D
Common Stock
2024-02-08
4
M
false
4600.00
1.93
A
11620.00
D
Common Stock
2024-02-08
4
S
false
4600.00
20.0106
D
7020.00
D
Common Stock
2024-02-09
4
M
false
4800.00
1.93
A
11820.00
D
Common Stock
2024-02-09
4
S
false
4800.00
20.0436
D
7020.00
D
Stock Option (Right to Buy)
1.93
2024-02-07
4
M
false
600.00
0.00
D
2030-12-15
Common Stock
600.00
154417.00
D
Stock Option (Right to Buy)
1.93
2024-02-08
4
M
false
4600.00
0.00
D
2030-12-15
Common Stock
4600.00
149817.00
D
Stock Option (Right to Buy)
1.93
2024-02-09
4
M
false
4800.00
0.00
D
2030-12-15
Common Stock
4800.00
145017.00
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 30, 2023.
Includes 850 shares purchased on November 15, 2022, 1,304 shares purchased on May 15, 2023 and 1,608 shares purchased on November 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.135, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date.
/s/ John R Moore Attorney-in-Fact for Behrad Derakhshan
2024-02-09